Download PDF
Aktuelle Urol 2012; 43(2): 112-114
DOI: 10.1055/s-0031-1283957
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Entzündungshemmende Medikamente und Prostatakarzinom: Aktueller Stand der Evidenz

Anti-Inflammatory Drugs and Prostatic Carcinoma: Current State of Evidence
H.-P. Schmid
1   Klinik für Urologie, Kantonsspital, St. Gallen
,
D. S. Engeler
1   Klinik für Urologie, Kantonsspital, St. Gallen
,
R Theiler
2   Klinik für Rheumatologie, Stadtspital Triemli, Zürich
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die epidemiologische Evidenz für einen protektiven Effekt von entzündungshemmenden Medikamenten gegen das Prostatakarzinom ist suggestiv aber nicht schlüssig beweisend. Studien dazu sind limitiert durch eine ungenügende Information über Dosierung und Dauer der Einnahme und durch methodische Verzerrungen. Zudem sollte ein möglicher Nutzen gegen die bekannten Nebenwirkungen bei Langzeitanwendung abgewogen werden.

Abstract

The epidemiological evidence for a protective effect of anti-inflammatory drugs against prostatic carcinoma is suggestive but not conclusive. Studies are limited by inadequate information on dose and duration of use and by methodological biases. Furthermore, potential benefits should be weighed against the known side effects of long-term use.

Schlüsselwörter

Prostatakarzinom - Entzündungen - nicht-steroidale Antirheumatika - Prävention

Key words

prostatic carcinoma - inflammation - non-steroidal anti-inflammatory drugs - prevention
 

  • Literatur

  • 1 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867
    CrossrefPubMedGoogle Scholar
  • 2 Caruso C, Lio D, Cavallone L et al. Aging, longevity, inflammation, and cancer. Ann N Y Acad Sci 2004; 1028: 1-13
    CrossrefPubMedGoogle Scholar
  • 3 Rostom A, Dubé C, Lewin G et al. Nonsteroidal anti-inflammatory drugs and cycooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146: 376-389
    CrossrefPubMedGoogle Scholar
  • 4 Corley DA, Kerlikowske K, Verma R et al. Protective association of aspirin / NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56
    CrossrefPubMedGoogle Scholar
  • 5 Sabichi AL, Lippman SM. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol 2004; 31: 36-44
    PubMedGoogle Scholar
  • 6 MacLennan GT, Eisenberg R, Fleshman RL et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006; 176: 1012-1016
    PubMedGoogle Scholar
  • 7 De Marzo AM, Marchi VL, Epstein JI et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-1992
    CrossrefPubMedGoogle Scholar
  • 8 Roberts RO, Bergstralh EJ, Bass SE et al. Prostatitis as a risk factor for prostate cancer. Epidemiology 2004; 15: 93-99
    CrossrefPubMedGoogle Scholar
  • 9 Badawi AF. The role of prostaglandin synthesis in prostate cancer. BJU Int 2000; 85: 451-462
    CrossrefPubMedGoogle Scholar
  • 10 Morita I. Distinct functions of COX-1 and COX-2. Prostalandins Other Lipid Mediat 2002; 68-69: 165-175
    PubMedGoogle Scholar
  • 11 O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-160
    PubMedGoogle Scholar
  • 12 Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997; 75: 1111-1118
    CrossrefPubMedGoogle Scholar
  • 13 Madaan S, Abel PD, Chaudhary KS et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000; 86: 736-741
    PubMedGoogle Scholar
  • 14 Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-1933
    CrossrefPubMedGoogle Scholar
  • 15 Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952
    CrossrefPubMedGoogle Scholar
  • 16 Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102
    CrossrefPubMedGoogle Scholar
  • 17 von Adelsberg J, Gann P, Ko AT et al. The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 2007; 23: 2063-2070
    CrossrefPubMedGoogle Scholar
  • 18 Jafari S, Etminan M, Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 2009; 3: 323-330
    PubMedGoogle Scholar
  • 19 Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010; 127: 1680-1691
    CrossrefPubMedGoogle Scholar
  • 20 Jacobs EJ, Newton CC, Stevens VL et al. A large cohort study of long-term Acetaminophen use and prostate cancer incidence. Epidemiol Biomarkers Prev 2011; 20: 1322-1328
    CrossrefPubMedGoogle Scholar